$VKTX Stock Surges Near $70 Mark Amid Positive Drug Trial News and Short Squeeze Expectations

$VKTX has seen a significant rise in its stock price, closing above $68 and nearing the $70 mark, a level it hasn't reached in over four months. The surge is attributed to $NVO's announcement that they need to conduct a Phase 2b trial, while $VKTX received approval to proceed directly to Phase 3. This development indicates that $VKTX's drug may be more advanced compared to $NVO's. $VKTX is trading up on the monlunabant CB1 data from $NVO. Market sentiment around $VKTX has shifted positively, with expectations of a short squeeze. The company is set to compete in a 200 billion dollar market.